Roivant’s mosliciguat cut pulmonary vascular resistance 56% in 16-week Phase 2 study
Topic: healthRegion: globalUpdated: i2 outletsSources: 5Spectrum: Mostly Center⏱ 2 min read📡 Wire pickup⚠ 3d+ old
Story Summary
SITUATION
Roivant said mosliciguat reduced pulmonary vascular resistance by 56% versus placebo in a 16-week Phase 2 study. The trial also met key secondary endpoints — a 35-meter placebo-adjusted six-minute walk improvement and a 53% NT-proBNP reduction — which Roivant said could advance treatment and strengthen its finances.
Coveragetap to expand ▾Spectrum: Mostly Center🌍US: 1 · Other: 1
Political Spectrum
Position is inferred from coverage mix.
i2 outlets · Center
Left
Center
Right
Left: 1
Center: 1
Right: 0
Geography Coverage
Distribution of where coverage is coming from.
i2 unique outlets · Dominant: US/Canada
KEY FACTS
- Roivant reported that mosliciguat achieved a 56% reduction versus placebo in pulmonary vascular resistance in a 16-week Phase 2 study.
- The study duration was 16 weeks and is described as a Phase 2 (mid-stage) trial.
- Roivant characterized the statistically significant results as a potential new treatment approach for pulmonary hypertension and said they could bolster the company’s financial health.
HISTORICAL CONTEXT
The immediate backdrop is the long-running clinical and commercial effort to treat pulmonary hypertension, especially forms secondary to interstitial lung disease (PH-ILD), where unmet need and high morbidity have driven repeated drug-development efforts since the 2000s.
Structurally, that effort has been shaped by regulatory approvals that established the nitric oxide–soluble guanylate cyclase (sGC) pathway and endothelin and phosphodiesterase-5 inhibitors as standard targets: bosentan’s FDA approval for pulmonary arterial hypertension in 2001, sildenafil’s PAH approval in 2005, and riociguat’s approval as an sGC stimulator in 2013.
Brief
Roivant said its experimental drug mosliciguat achieved the goals of a 16-week Phase 2 study, including a 56% placebo-adjusted reduction in pulmonary vascular resistance. The company said the statistically significant results could open a new treatment approach for pulmonary hypertension and bolster Roivant’s finances.
Sources
5 of 5 linked articles
Roivant Reports 56.3% Placebo-Adjusted PVR Reduction In Phase 2 Mosliciguat PH-ILD Study, Starts Phase 3 PHrontier Trial - Pulse 2.0
pulse2.comSep 9Left
↗
Roivant's mosliciguat posts standout Phase 2 win in pulmonary hypertension linked to lung disease
app.dealroom.coSep 9Left
↗
Roivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data
biospace.comSep 8Left
↗
Roivant reports Phase II goals met in mosliciguat study
ua.newsSep 8Left
↗
Roivant’s mosliciguat cut pulmonary vascular resistance 56% in 16-week Phase 2 study
statnews.comSep 8Left
↗